Sam Altman's Portfolio in 2026: OpenAI at $852B, Helion at $15.5B

OpenAI closed a $122 billion funding round at an $852 billion valuation in March 2026, per Forbes, but Sam Altman's capital footprint extends well beyond the company that made him famous. Across four distinct ventures, Altman has committed, co-founded, or personally seeded enterprises in fusion energy, biometric identity, and longevity science, each at a different stage of the risk curve.

OpenAI: $20B ARR and the Countdown to a 2027 IPO

OpenAI's annualized revenue run rate reached $20 billion by the end of 2025, up from roughly $6 billion the year prior, according to statements from CEO Sam Altman and CFO Sarah Friar reported by Yahoo Finance. The company's internal projections, reported by Fortune in February 2026, target $280 billion in annual revenue by 2030.

The capital structure underpinning that growth is substantial. OpenAI's $122 billion March round was co-led by SoftBank alongside Andreessen Horowitz, D.E. Shaw, Nvidia, and Amazon, per Forbes. That brings total committed data center investment to approximately $1.4 trillion over eight years, a figure Altman himself cited publicly. The company completed its for-profit restructuring in October 2025, converting to OpenAI Group PBC while keeping the nonprofit OpenAI Foundation as a major equity holder. OpenAI filed a confidential S-1 on June 8, 2026, but is now targeting a 2027 IPO, according to Bloomberg. That same Bloomberg report noted OpenAI proposed offering a 5 percent equity stake to the US government as part of a broader regulatory arrangement.

One outstanding question concerns Altman's personal stake. OpenAI had discussed granting him approximately 7 percent equity as part of the for-profit conversion, per Bloomberg's 2024 reporting, though Altman publicly said at the time that no such plan was finalized. The S-1 filing will settle the question. For more on how the broader market views OpenAI's capital structure, see SoftBank's $65B OpenAI Bet Sparks Investor Concern.

Helion Energy: Altman Owns a Third of a $15.5B Fusion Startup

Helion Energy raised $465 million in June 2026 at a post-money valuation of $15.5 billion, per reporting from TechCrunch and GeekWire, bringing total capital raised above $1.5 billion. The round more than tripled the company's valuation from $5.4 billion in January 2025, when it closed a $425 million Series F.

Altman's ownership position became public during litigation. Court disclosures from the Musk v. Altman trial revealed that he holds roughly one-third of Helion, where he serves as executive chairman. At the June 2026 valuation, that implies a stake worth approximately $5 billion on paper. The company's stated objective is to deliver fusion-generated electricity to Microsoft's grid by 2028, per the TechCrunch report. Microsoft's power-purchase agreement with Helion, first announced in 2023, remains the central commercial milestone the company is racing to meet.

Fusion energy has a decades-long history of missed deadlines, but Helion's approach, which uses helium-3 as fuel and recovers energy from a collapsing magnetic field, is distinct from the tokamak designs pursued by ITER and Commonwealth Fusion Systems. Whether the 2028 target holds will be tested over the next 18 months as the company moves from its seventh-generation Polaris device into engineering for the actual power plant.

World and Retro Biosciences: Identity Infrastructure and the Longevity Science Bet

World, formerly known as Worldcoin, raised $52.5 million through a strategic crypto token sale on July 24, 2026, per TechCrunch. The company, co-founded by Altman, has iris-scanned and verified approximately 17.5 million users using its Orb device, and is repositioning itself as identity infrastructure for the AI era, signing enterprise integrations with Zoom and Docusign. The argument is straightforward: as AI-generated deepfakes proliferate, organizations need a reliable signal that the person on the other side of a video call or document signature is human. World's iris hash provides that signal without transmitting biometric data to third parties.

Retro Biosciences sits at an even earlier stage of the risk curve. Altman personally provided the company's entire $180 million seed round in 2023, as reported by MIT Technology Review. As of May 2026, the company is valued at $1.8 billion, per STAT News, having raised a broader funding round. Retro's stated mission is to add ten healthy years to the human lifespan using a combination of AI, in-vivo gene therapies, and cell-replacement approaches. Its first clinical trial, testing a pill targeting protein aggregates in Alzheimer's patients, was described by CEO Joe Betts-LaCroix as going "super good" with no dose-limiting toxicities, per STAT News.

What It Means

Altman's portfolio is a study in risk concentration across long time horizons. OpenAI is already a commercial business generating $20 billion in annualized revenue and moving toward a public listing. Helion is a capital-intensive hardware bet on a technology that has never been commercialized, with an 18-month runway to its first grid-scale milestone. World is a consumer-facing crypto-adjacent network pivoting to enterprise before it has proven unit economics. Retro is pre-revenue science. What they share is a common premise: that AI will create new categories of human vulnerability, whether in energy supply, identity verification, or longevity, that existing institutions are not equipped to solve. Whether that premise converts into returns is a question the next two to three years will begin to answer.

Sources

• Forbes: OpenAI Valuation Reaches $852 Billion After Massive Funding Round
• Yahoo Finance: Sam Altman Says OpenAI Has $20B ARR
• Fortune: OpenAI Revenue Forecast $280 Billion by 2030
• Bloomberg: OpenAI Proposes Giving the US Government a 5 Percent Stake
• TechCrunch: Helion Raises $465M to Build a Power Plant for Microsoft
• GeekWire: Helion Hits $15.5B Valuation With $465M in New Cash
• TechCrunch: Sam Altman's Biometric Startup World Raises $52.5M via Crypto Sale
• MIT Technology Review: Sam Altman Invested $180 Million in Retro Biosciences
• STAT News: Retro Biosciences Latest Fundraising Values It at $1.8 Billion

Editorial standards: every claim is sourced. Tips: [email protected]